CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.44B, above the global median of $1.15B
- FinancialsAltman Z-Score -1.41: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.44BUSDvs all stocks (USD)
Revenue (TTM)
114.48MUSDvs all stocks (USD)
Profit Margin
-118.74%vs Biotechnology peers
Beta
-0.1090xvs all stocks
52-Week Change
122.22%vs all stocks
Market Capitalization
1.44BUSDvs all stocks (USD)
Enterprise Value
1.44BUSDvs all stocks (USD)
Forward P/E
15.82xvs Biotechnology peers
Price to Sales (TTM)
12.56xvs Biotechnology peers
Enterprise to Revenue
12.55xvs Biotechnology peers
Enterprise to EBITDA
-10.38xvs Biotechnology peers
Gross Margin
92.44%vs Biotechnology peers
Profit Margin
-118.74%vs Biotechnology peers
Operating Margin
-57.37%vs Biotechnology peers
Return on Assets (TTM)
-54.70%vs Biotechnology peers
Revenue (TTM)
114.48MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.11USDUpdated Jul 9, 2026Quarterly Revenue Growth
198.44%vs Biotechnology peers
Gross Profit (TTM)
58.47MUSDvs all stocks (USD)
EBITDA (TTM)
-138.45MUSDvs all stocks (USD)
Net Income (TTM)
-135.94MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-89.32MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-183.44MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 9, 2026Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Apr 30, 2025Operating Income
-182.98MUSDvs all stocks (USD)
Pre-tax Income
-180.05MUSDFY2025 · Apr 30, 2025Income Tax Expense
3.39MUSDFY2025 · Apr 30, 2025Net Income
-183.44MUSDFY2025 · Apr 30, 2025EBIT
-174.27MUSDFY2025 · Apr 30, 2025EBITDA (Income Statement)
-175.61MUSDFY2025 · Apr 30, 2025Research & Development
71.71MUSDFY2025 · Apr 30, 2025Selling, General & Administrative
116.29MUSDFY2025 · Apr 30, 2025Non-operating Interest Income
6.43MUSDFY2025 · Apr 30, 2025Non-operating Interest Expense
5.79MUSDFY2025 · Apr 30, 2025EPS (Basic)
-3.69USDFY2025 · Apr 30, 2025EPS (Diluted)
-3.69USDFY2025 · Apr 30, 2025Basic Shares Outstanding
49.65MSharesFY2025 · Apr 30, 2025Diluted Shares Outstanding
49.65MSharesFY2025 · Apr 30, 2025Net Income from Continuing Operations
-183.44MUSDFY2025 · Apr 30, 2025Operating Cash Flow
-162.01MUSDFY2025 · Apr 30, 2025Free Cash Flow
-162.44MUSDFY2025 · Apr 30, 2025Cash & Cash Equivalents (End of Period)
132.27MUSDFY2025 · Apr 30, 2025Starting Profit (CF Statement)
-183.44MUSDFY2025 · Apr 30, 2025Depreciation & Amortization
941.00KUSDFY2025 · Apr 30, 2025Stock-based Compensation
12.29MUSDFY2025 · Apr 30, 2025Other Non-cash Items
6.24MUSDFY2025 · Apr 30, 2025Change in Accounts Receivable (CF)
-3.62MUSDFY2025 · Apr 30, 2025Change in Accounts Payable (CF)
-4.97MUSDFY2025 · Apr 30, 2025Change in Other Assets/Liabilities
10.56MUSDFY2025 · Apr 30, 2025Capital Expenditures
-434.00KUSDFY2025 · Apr 30, 2025Purchase of Investments
-30.57MUSDFY2025 · Apr 30, 2025Sale of Investments
122.52MUSDFY2025 · Apr 30, 2025Net Investing Cash Flow
91.52MUSDFY2025 · Apr 30, 2025Other Financing Charges
98.04MUSDFY2025 · Apr 30, 2025Net Financing Cash Flow
153.95MUSDFY2025 · Apr 30, 2025Shares Outstanding
51.24MSharesUpdated Jul 9, 2026Float Shares
38.18MSharesUpdated Jul 9, 2026Shares Short
6.84MSharesUpdated Jul 9, 2026Short Ratio
0.9400daysvs all stocks
Short % of Shares Outstanding
14.37%vs all stocks
% Held by Insiders
1.72%vs all stocks
% Held by Institutions
136.88%vs all stocks
Total Cash (MRQ)
285.03MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.35USDUpdated Jul 9, 2026Total Debt (MRQ)
284.31MUSDvs all stocks (USD)
Current Ratio (MRQ)
5.17xvs Biotechnology peers
Book Value per Share (MRQ)
-0.3840USDUpdated Jul 9, 2026Total Assets
335.38MUSDvs all stocks (USD)
Total Current Assets
320.15MUSDFY2025 · Dec 31, 2025Total Liabilities
338.09MUSDFY2025 · Dec 31, 2025Total Non-current Assets
15.23MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
280.73MUSDFY2025 · Dec 31, 2025Total Current Liabilities
57.35MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
229.34MUSDFY2025 · Dec 31, 2025Other Short-term Investments
70.87MUSDFY2025 · Dec 31, 2025Accounts Receivable
2.59MUSDFY2025 · Dec 31, 2025Inventory
3.43MUSDFY2025 · Dec 31, 2025Accounts Payable
8.27MUSDFY2025 · Dec 31, 2025Short-term Debt
1.62MUSDFY2025 · Dec 31, 2025Deferred Revenue
0.00USDFY2025 · Dec 31, 2025Other Current Liabilities
13.57MUSDFY2025 · Dec 31, 2025Long-term Debt
149.95MUSDFY2025 · Dec 31, 2025Common Stock (Book)
51.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-762.69MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-2.71MUSDvs all stocks (USD)
52-Week Low
9.83USDUpdated Jul 9, 202652-Week High
27.00USDUpdated Jul 9, 202652-Week Change
122.22%vs all stocks
Beta
-0.1090xvs all stocks
50-Day MA
24.15USDUpdated Jul 9, 2026200-Day MA
16.91USDUpdated Jul 9, 2026Avg 10-Day Volume
2.09MSharesUpdated Jul 9, 2026Avg 30-Day Volume
3.21MSharesUpdated Jul 9, 2026Diluted EPS (TTM)
-3.94USDUpdated Jul 9, 2026Other Income / Expense
2.28MUSDFY2025 · Apr 30, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.92Profit Margin: -1.19
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 5.17Altman Z-Score: -1.41
Financial Health
Altman Z-Score -1.41: distress zoneCritical
Altman Z-Score: -1.41
Low earnings qualitySignificant
Earnings Quality Score: -0.54
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.44B, above the global median of $1.15BNotable
Market cap (USD): 1,437,503,976Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
HBM Holdings Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shandong Xinhua Pharmaceutical Company Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Inspire Medical Systems, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chongqing Genrix Biopharma Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai MicroPort EP MedTech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Vcanbio Cell & Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangxi Fushine Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Hotgen Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Concord Biotech Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Qingdao Haier Biomedical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow